Australia’s first medical cannabis course, designed for health care practitioners, by health care practitioners.
Written & Presented by Dr David Caldicott
Mike has a brain tumour. With over 100 years of negative propaganda behind him, Mike sets off on a journey to unearth the reality of patient access to medicinal cannabis in Australia…
Join us for the world premiere of the feature length documentary, ‘High as Mike’.
Mike has a brain tumour.
With over 100 years of negative propaganda behind him, Mike sets off on a journey to unearth the reality of patient access to medicinal cannabis in Australia.
This documentary will change your perception of cannabis and leave you asking why!
Join us for the world premiere of the feature length documentary, ‘High as Mike’.
Tickets are sold separately for those who are not attending the Symposium. Passes must be presented on entry
Friday 22nd March | 7.30pm-9pm
Venue: The Showroom at the Twin Towns Conference Centre Wharf Street, Tweed Heads NSW
Cost: $20 per head
(Tickets included for 3 day & Friday Symposium attendees)
Dress up and mingle with the Symposium Keynote Speakers, Special Invited Guests and the Production Team for High as Mike at this exclusive ticketed event.
Friday 22nd March commencing 6.30pm NSW Time
Beer or Champagne and canapes served in the Starr’s Room at the Twin Towns Conference Centre Wharf Street, Tweed Heads NSW.
Cost: $50.00 per person for canapes and one drink on arrival. Additional drinks can be purchased from the bar.
Attendees will be required to purchase their tickets before the event 14/03 for catering purposes. No tickets available on the night. Tickets must be presented upon entry.
A chance to network, meet hosts and keynote speakers.
Includes 3 course dinner
Exciting announcements still to come!
Saturday 23rd March | 7.30pm – late
Venue: The Showroom at the Twin Towns Conference Centre Wharf Street, Tweed Heads NSW
Dress Code: Cocktail attire
3 Course dinner & drinks
Cost: $150 per head
Sponsored by Spectrum Cannabis as a major fundraiser for United in Compassion
Donald I. Abrams, MD. is the past chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco…
Donald I. Abrams, MD. is the past chief of the Hematology-Oncology Division at San Francisco General Hospital and a Professor of Clinical Medicine at the University of California San Francisco.
He has an Integrative Oncology consultation practice at the UCSF Osher Center for Integrative Medicine. He received an A.B. in Molecular Biology from Brown University in 1972 and graduated from the Stanford University School of Medicine in 1977.
After completing an Internal Medicine residency at the Kaiser Foundation Hospital in San Francisco, he became a fellow in Hematology/Oncology at the Cancer Research Institute of the University of California, San Francisco in 1980. He was one the original clinician/investigators to recognize and define many early AIDS-related conditions.
He has long been interested in clinical trials of complementary medicine interventions for HIV/AIDS and cancer, including evaluations of medicinal marijuana. In 1997 he received funding from the National Institute on Drug Abuse to conduct a clinical trial of the short-term safety of cannabinoids in HIV infection. Subsequently he was granted funds by the University of California Center for Medicinal Cannabis Research to conduct a placebo-controlled study of smoked cannabis in patients with painful HIV-related peripheral neuropathy as well as a study evaluating vaporization as a smokeless delivery system for medicinal.
His last NIH-funded trials investigated the possible pharmacokinetic interaction between vaporized cannabis and opioid analgesics in patients with chronic pain and a study of vaporized THC:CBD cannabis in patients with Sickle Cell disease.
He co-authored the chapter on “Cannabinoids and Cancer” in the Oxford University Press Integrative Oncology text that he co-edited with Andrew Weil. He co-edits the NCI PDQ CAM Cannabinoids and Cancer website.
He was a member of the National Academies of Sciences, Engineering and Medicine’s committee that published The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research in January 2017.
Principal Investigator, Technion Israel Institute of Technology, Laboratory of Cancer Biology and Cannabinoid Research…
Principal Investigator, Technion Israel Institute of Technology, Laboratory of Cancer Biology and Cannabinoid Research
David (Dedi) Meiri, PhD, is an Assistant Professor at the Faculty of Biology at the Technion Israel Institute of Technology and a member of the Technion Integrated Cancer Center (TICC). Dr. Meiri’s scientific background is highly diverse. He holds a M.Sc. in biochemistry and a Ph.D. in plant biotechnology from Tel Aviv University. Dr. Meiri conducted his post-doctoral fellowship at the Ontario Cancer Institute where he focused on the role of the GEF-H1 protein in tumor invasion and metastasis. During his post-doctoral studies, he expanded his knowledge in human biology and cancer pathogenesis and succeeded within a very short time frame to receive worldwide recognition as an expert in the fields of G-protein coupled receptors (GPCRs) and small GTPases. Upon completion of his post-doctoral fellowship, Dr. Meiri took a position at the Technion Israel Institute of Technology, where he heads the “Laboratory of Cancer Biology and Cannabinoid Research”.
Presently, his lab investigates the therapeutic potential of phytocannabinoids, the unique active compounds of the Cannabis sativa plant. On top of other research being conducted in the lab, the main focus of his research is to determine the antitumor effects of cannabinoids, including the anti-metastatic and pro-apoptotic effects of phytocannabinoids.
In addition to the laboratory cannabis research performed on-site, Dr. Meiri collaborates with cannabis growers, clinicians, major manufacturers and distributors of medical cannabis for the purpose of revolutionizing cannabis treatment. He is operating the “Cannabis Database Project” and his lab is currently involved in eight clinical trials covering diverse aspects of cannabis treatment such as colon disease, pain prevention, cancer treatment and epilepsy.
Dr. Meiri is also highly involved in governmental regulations and is a residing member in several Israeli Ministry of Health committees which seek to advance the fundamental understanding of optimal cannabis usage and minimization of adverse side effects.
Cam Battley is Chief Corporate Officer of Aurora Cannabis, one of the world’s largest and fastest growing cannabis companies. A passionate spokesperson for the medical cannabis industry, Cam started with Aurora Cannabis in March 2016…
Chief Corporate Officer
Aurora Cannabis Inc.
Cam Battley is Chief Corporate Officer of Aurora Cannabis, one of the world’s largest and fastest growing cannabis companies. A passionate spokesperson for the medical cannabis industry, Cam started with Aurora Cannabis in March 2016 and has been a key driver to Aurora’s emergence as a global leader.
As a senior healthcare industry leader and strategist with more than 20 years of international experience, Cam is the lead external-facing executive of Aurora, responsible for establishing and managing relationships with shareholders, analysts, media, regulators, governments, and other companies and organizations operating in the cannabis sector. He also chairs the Executive Committee, acts as liaison with the Board, and ensures organizational alignment across the Company’s operations, domestic and international.
Cam is a member of the Board of Directors of Cannabis Canada, the trade association of Licensed Producers. With a background as a health sector management consultant, he brings experience in government, health- care NGOs, and the biopharmaceutical industry.
Prior to joining Aurora, Cam was Vice President of Communications and Corporate Development for Bedrocan Canada, an experienced world-wide producer of legal cannabis. During his time there, Cam was the primary spokesperson and responsible for media, external communications, investor relations, business development, government relations, and physician and patient initiatives. Cam’s leadership generated significant media coverage for Bedrocan.
In 1997, Cam founded Health Strategy Group, an international management consultancy with clients ranging from health professional and patient NGOs, to innovative and generic pharmaceutical firms, and biotechnology and medical device companies. While there, Cam established himself as an expert speaker and communicator and was retained to provide media training for executives and health professionals throughout the industry.
Before founding Health Strategy Group, Cam was Vice President, Creative, of Veritas Communications. Under Cam’s leadership, Veritas grew from six to 24 employees, becoming Canada’s largest health care communications firm.
Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Director of Research and Development of the International Cannabis and Cannabinoids Institute…
Dr Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Director of Research and Development of the International Cannabis and Cannabinoids Institute (ICCI) based in Prague, Czech Republic: https://www.icci.science
ICCI is a “center of excellence” comprised of a consortium of international academic institutions and private companies dedicated to promotion of medical cannabis research and industrial hemp nutrition and husbandry.
Previously, he was Medical Director of PHYTECS (2015-2017), a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system (http://www.phytecs.com), and from 2003-2014, he served as Senior Medical Advisor, medical monitor and study physician to GW Pharmaceuticals, United Kingdom for numerous Phase I-III clinical trials of Sativex® for alleviation of cancer pain unresponsive to optimized opioid treatment and initial studies of Epidiolex® for intractable epilepsy (https://www.gwpharm.com).
He graduated from the University of Pennsylvania (Psychology), and the University of Massachusetts Medical School, before residencies in Pediatrics in Phoenix, Arizona and in Child and Adult Neurology at the University of Washington in Seattle. He was a clinical neurologist in Missoula, Montana for 20 years in a practice with a strong chronic pain component. In 1995, he pursued a 3-month sabbatical doing ethnobotanical research with the Machiguenga people in Parque Nacional del Manu, Peru.
He has held faculty appointments in Pharmaceutical Sciences at the University of Montana, in Medicine at the University of Washington, and as visiting professor, Chinese Academy of Sciences, Harvard, and Johns Hopkins University.
He is a Past-President of the International Cannabinoid Research Society and is former Chairman of the International Association for Cannabinoid Medicines. He serves on the Scientific Advisory Board for the American Botanical Council. He is author of Handbook of Psychotropic Herbs, co-editor of Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential, and author of The Last Sorcerer: Echoes of the Rainforest. He was founding editor of Journal of Cannabis Therapeutics, selections of which were published as books: Cannabis Therapeutics in HIV/AIDS, Women and Cannabis: Medicine, Science and Sociology, Cannabis: From Pariah to Prescription, and Handbook of Cannabis Therapeutics: From Bench to Bedside. He has also published numerous book chapters, and over fifty articles in neurology, pain management, cannabis, and ethnobotany. His research interests have included correlations of historical uses of cannabis to modern pharmacological mechanisms, phytopharmaceutical treatment of migraine and chronic pain, herbal synergy and phytocannabinoid/terpenoid, serotonergic and vanilloid interactions.
He has consulted or lectured on these topics in 39 US states and Canadian provinces and 39 countries.
Jeffrey Hergenrather, MD is a general practitioner specializing in cannabis / cannabinoid medicine since 1999…
Dr Jeffrey Hergenrather, MD is a general practitioner specializing in cannabis / cannabinoid medicine since 1999.
His medical experience includes 26 years in emergency medicine and private general practice that includes the use of cannabis since 1977. He continues in an active consultation practice in northern California with face-to-face, telephone, and on-line consultations for the use of cannabis as medicine.
In 2018 Graham opened the first medical cannabis service in Aotearoa NZ. Cannabis Care Clinic is in Henderson, Auckland providing specialist consultations for legal medicinal cannabis prescriptions…
MB ChB, Dip Obs, PGDip Med Sc (Addiction), FRNZCGP, FAChAM
In 2018 Graham opened the first medical cannabis service in Aotearoa NZ. Cannabis Care Clinic is in Henderson, Auckland providing specialist consultations for legal medicinal cannabis prescriptions. Problems addressed include chronic pain, cancer symptoms, anxiety, chronic insomnia and neurological conditions. Most patients have experienced little benefit or adverse effects from conventional treatment or have been told there are no further treatments. Many report that medicinal cannabis offers symptom relief, improved quality of life and most importantly, restores hope.
His part time general practice experience dates from 1983. Much of this work involves assessing and managing addictions and/or chronic pain. He is a FRNZCGP.
Graham completed his Fellowship of the Australasian Chapter of Addiction Medicine (FAChAM) in 2008. As an Addiction Specialist he manages problems such as alcohol and drug withdrawal, opioid substitution treatment, medication for chronic pain and he writes addiction assessments.
Dr. Mark Ware is currently the Chief Medical Officer of Canopy Growth Corporation. He previously served as Director of Clinical Research of the Alan Edwards Pain Management Unit…
Dr. Mark A. Ware MBBS MRCP(UK) MSc
Dr. Mark Ware is currently the Chief Medical Officer of Canopy Growth Corporation. He has taken a leave of absence as Associate Professor in Family Medicine and Anesthesia at McGill University from July 2018 to work in this capacity.
He previously served as Director of Clinical Research of the Alan Edwards Pain Management Unit at the McGill University Health Centre for over 10 years, and was the Executive Director of the non-profit Canadian Consortium for the Investigation of Cannabinoids since 2007.
He has served as co-director of the FRQS-supported Quebec Pain Research Network, and sat on the executive management team of the Alan Edwards Centre for Research on Pain at McGill University. His research has been funded and supported by CIHR, FRQS, private foundations and pharmaceutical companies.
He has published over 100 papers on cannabis and pain research in academic journals, has written 6 book chapters, and has given hundreds of lectures to health professionals and the public on cannabis over the last 20 years. He has served as a consultant to several large corporate and academic research programs internationally. He has advised the Canadian federal government on cannabis policy since 2001, and 2016, he served as the vice chair of the Federal Task Force on the Legalization and Regulation of Cannabis in Canada.
MD, PhD, FRACS from the Austin health, University of Melbourne will speak on “The role of cannabinoids in the treatment of pancreatic cancer”. He has over 150 peer-reviewed publications and has contributed to leading surgical texts…
MD, PhD, FRACS
Austin health, University of Melbourne
“The role of cannabinoids in the treatment of pancreatic cancer”
Background: Advanced and minimally invasive liver, pancreatic and biliary surgeon with a focus on pancreatic cancer research. Laboratory head of pancreatic cancer biology group. Clinical research: Advanced and minimally invasive pancreatic resection techniques. Borderline resectable pancreatic cancers. Neoadjuvant and adjuvant chemotherapy trials. Brachytherapy for treatment of pancreatic cancer. Enhanced post -operative recovery techniques. Fluid sparing therapies in pancreatic surgery. Familial pancreatic cancer screening.
Basic Research: Mouse models of pancreatic cancer. K-ras targeted therapies. Role of P-21 Kinase in the development and progression of pancreatic cancer. Novel therapies for the treatment of pancreatic cancer including use of Cannabis
Contribution to the field of research: I have over 150 peer-reviewed publications. I have written one book and have contributed 4 book chapters in leading surgical texts. I have publications in the highest ranked surgical journals that include Annals of Surgery, British Journal of Surgery, World Journal of Surgery and Annals of Surgical Oncology. I have co-authored five publications in Nature and two in Cancer Letters. I have had 40+ international presentations and 2000+ listed citations relating to my published work. I am a member of Victorian Integrated Cancer Services, Cancer Council and Victorian State Government committees developing guidelines to improve patient outcomes with pancreatic cancer.
Dr Towpik has been a General Practitioner in Australia since 1993 and an advocate of medicinal cannabis since the law was amended and cannabis was legalised for medicinal use…
Dr Towpik has been a General Practitioner in Australia since 1993 and an advocate of medicinal cannabis since the law was amended and cannabis was legalised for medicinal use. Since then she has been studying the therapeutic properties of cannabis, how it works in the human body and the potential applications in General Practice, especially in the management of chronic debilitating pain.
In 2016, Dr Towpik founded MediHuanna, an organisation that provides science-based medicinal cannabis education for Health Professionals. Dr Towpik sees cannabis as a therapeutic agent that has huge potential in General Practice. Her goal is to change the stigma of cannabis through education, enabling it to be seen as an important medicine that should be integrated into modern medicine.
One of the most clinically knowledgeable physicians in the U.S. in the field of medicinal cannabis. He has spent 40 years working in substance and drug abuse treatment and prevention programs…
One of the most clinically knowledgeable physicians in the U.S. in the field of medicinal cannabis. He has spent 40 years working in substance and drug abuse treatment and prevention programs. Dr. Bearman was a pioneer in the free and community clinic movement. His career includes public health, administrative medicine, provision of primary care, pain management and cannabinology.
His almost 40 year professional experience in the drug abuse treatment and prevention field includes being the Co-Director of the Haight-Ashbury Drug Treatment Program, being a member of Governor Reagan’s Inter Agency Task Force on Drug Abuse, a member of both the Santa Barbara and the San Diego County Drug Abuse Technical Advisor Committees, and a consultant to Hoffman-LaRoche, Santa Barbara County Schools and the National PTA. He has been recognized by the Santa Barbara Medical Society with the Humanitarian Recognition Award.
Dr. Bearman is also the author of Drugs Are NOT the Devil’s Tools: How Discrimination and Greed Created a Dysfunctional Drug Policy and How It Can Be Fixed in 2 volumes.
Since 1976 ‘Amazon’ John Easterling has been an explorer and treasure hunter in the Amazon rainforest where curanderos taught him plant medicine. His original degree is in environmental studies…
Since 1976 ‘Amazon’ John Easterling has been an explorer and treasure hunter in the Amazon rainforest where curanderos taught him plant medicine. His original degree is in environmental studies. His 28 years of rainforest plant medicine experiences have been profiled on TV and in documentaries. Amazon John’s passion for cannabis medicine began with his first cultivation in 1970. He currently maintains a research garden of multiple cultivars in California and is co-owner of a licensed cannabis farm in Oregon.
Jonathan Zaid is the Director of Advocacy and Corporate Social Responsibility at Aurora Cannabis Inc., one of the world’s largest legal cannabis companies…
Director, Advocacy and Corporate Social Responsibility
Aurora Cannabis Inc. (TSX: ACB)
Jonathan Zaid is the Director of Advocacy and Corporate Social Responsibility at Aurora Cannabis Inc., one of the world’s largest legal cannabis companies. His responsibilities include overseeing the development and implementation of Aurora’s global CSR and advocacy initiatives. Jonathan also sits on the C3 industry association’s Medical Cannabis Committee.
Since 2014 when he founded Canada’s foremost non-profit cannabis patient advocacy organization, Canadians for Fair Access to Medical Marijuana (CFAMM), Zaid has been recognized as a leading expert on cannabis policy, education, and advocacy. Jonathan served as CFAMM’s Executive Director from 2014 to 2018.
Zaid’s unwavering commitment to advocacy has already and continues to transform policy among governments, insurers, and industry, and is regularly featured in major media outlets. Jonathan has been honoured by multiple awards, including being named one of five “Mavericks and Movers” by the Financial Post.
Dr Alex Wodak is a physician and the President of the Australian Drug Law Reform Foundation and a Director of Australia 21. He was Director of the Alcohol and Drug Service, St Vincent’s Hospital, Sydney, from 1982 until he retired in 2012…
Dr Alex Wodak is a physician and the President of the Australian Drug Law Reform Foundation and a Director of Australia 21. He was Director of the Alcohol and Drug Service, St Vincent’s Hospital, Sydney, from 1982 until he retired in 2012.
Together with colleagues, he started Australia’s first needle syringe programme (to slow the spread of HIV) in 1987 and Australia’s first medically supervised injecting centre (1999). Both were pre-legal at the time. Dr Wodak was the Foundation President of the International Harm Reduction Association (1996-2004) and helped to establish the National Drug and Alcohol Research Centre (1987), the NSW Users AIDS Association (1989), and the Australian Society of HIV Medicine (1989).
Justin is a Pharmacognosist & Educator, and has spent decades exploring the diverse field of herbal medicine, both from a scientific and traditional ethnopharmacological perspective…
M.HerbMed (USyd) BHSc (Nat)(UNE)
ND DBM DRM Dip Nutrition
Justin is a Pharmacognosist & Educator, and has spent decades exploring the diverse field of herbal medicine, both from a scientific and traditional ethnopharmacological perspective.
Working in education since 2003, Justin has taught across a wide variety of subjects encompassing medical sciences such as anatomy, physiology, integrated pharmacology and clinical pathology to plant specific sciences such as pharmacognosy / phytochemistry, herbal manufacturing and medicinal botany. He has worked as a research and development consultant to the educational and healthcare industries since 2006.
Key areas of study in his Masters degree with the Faculty of Pharmacy at Sydney University were toxicology, pharmacognosy, analytical phytochemistry, medicinal botany and pharmaceutical technology.
Over the last decade, his research interests encompass Medicinal Cannabis, cannabinoid based pharmacology, novel drug development, full spectrum plant extracts and plant based pharmacology for pain, inflammation and immune modulation.
His current clinical interests include pain management, mental health disorders and herb drug interactions.
David has worked as a specialist emergency physician for 25 years, is a senior university lecturer and adjunct associate professor..
Adjunct Associate Professor, University Of Canberra
Emergency Specialist Doctor
David has worked as a specialist emergency physician for 25 years, is a senior university lecturer and adjunct associate professor.
A founding member of the Australian Medical Cannabis Observatory; the AMCO was created to establish the infrastructure and support systems that an industry will require.
Author of numerous publications, a researcher, educator, with specialties in Novel Illicit Compounds in the ED, Simulation, Medical Education, Innovation in the Emergency Department, Medical Response to Terrorism, Disaster Medicine
Iain McGregor is Professor of Psychopharmacology, NHMRC Principal Research Fellow and Academic Director of the Lambert Initiative for Cannabinoid Therapeutics…
Iain McGregor is Professor of Psychopharmacology, NHMRC Principal Research Fellow and Academic Director of the Lambert Initiative for Cannabinoid Therapeutics located within the Brain and Mind Centre at the University of Sydney.
Iain was born in Scotland and was trained in Experimental Psychology and Psychopharmacology. He has a strong research interest in the area of medicinal cannabis with more than 20 years of experience working in the science of cannabis and the cannabinoids.
The Lambert Initiative for Cannabinoid Therapeutics had its genesis at the inaugural United in Compassion symposium in Tamworth in 2014 and aims to fast track research into the therapeutic benefits of cannabinoids in conditions such as epilepsy, anxiety, pain and cancer. It includes major preclinical and clinical programs of research involving around 30 staff and students. The Lambert Initiative is also strongly involved in education, outreach and advocacy and vocal around issues such as patient access, medical necessity and roadside drug testing.
Iain has diverse interests outside of medicinal cannabis. These include the science of pheromones; conservation of Australian marsupial carnivores; and also the role of oxytocin in social behavior. He is a founder of the new spinoff company Kinoxis Therapeutics that is developing a new oxytocin-derived therapeutic called SOC-1 for the treatment of addictions, social anxiety and autism.
Outside of the lab, Iain keeps himself busy as a songwriter, sound engineer and mountain biker.
Professor Laurie Mather Started out as analytical and product development chemist for multinational pharmaceutical company in 1958…
Laurie Mather DMedSc PhD, Emeritus Professor of Anaesthesia, The University of Sydney
Professor Laurie Mather Started out as analytical and product development chemist for multinational pharmaceutical company in 1958. He developed interests in pharmacology related to anaesthesia and pain management as a postgraduate research student during the mid-1960s while teaching chemistry to pharmacy students.
He performed research project with pharmacognosist Lorna Cartwright in 1971 to measure main constituents in Australian grown cannabis seized by police.
Prof.Mather worked in academic departments of anaesthesia in the USA, UK and South Australia from 1972; returned to Sydney in 1991 to establish the Centre for Anaesthesia and Pain Management Research at the Royal North Shore Hospital and University of Sydney with colleague Michael Cousins
Prof. Mather is a member of the Working Party on the Use of Cannabis for Medicinal Purposes convened by NSW Premier Carr in 2000; he unsuccessfully sought federal and state research grants in 2002-2004 to convene a scientific-medical consortium to establish a sound basis of cannabinoid pharmacotherapy for patients; he also contributed to various subsequent federal and state inquiries and to lay media on issues concerning medicinal cannabis.
Prof. Mather has published numerous articles mainly concerned with the pharmacology of anaesthetic, analgesic and cannabinoid drugs, and methods of drug delivery. Retired in 2007, he was appointed Emeritus Professor of Anaesthesia, Sydney Medical School.
Simon Eckermann is Senior Professor of Health Economics at the Australian Health Services Research Institute and the University of Wollongong…
Simon Eckermann is Senior Professor of Health Economics at the Australian Health Services Research Institute and the University of Wollongong. He was previously Health Economics Professor at the Flinders University Centre for Clinical Change and Health Care Research and Senior Health Economist at the NHMRC Clinical Trial Centre. He is a CI on competitive research grants totalling more than A$28 million since 2005 and actively sits on and undertakes guideline revision and health economics educational activities for National decision bodies including the Pharmaceutical Benefits Advisory Committee Economic Sub-Committee (PBAC ESC 2005-2010), National Palliative Care Trials Scientific Committee (2006-2014), Prostheses List Advisory Committee (2012-2014), Victorian Cancer Agency (2015-) and Food Standards ANZ (2017-) as well as various NHMRC grant review committees.
His original research and collaborations have established missing links between optimal decision making in research, reimbursement and regulation in practice and are extensively published in the highest impact health economics and decision making journals, and clinical and policy journals with his applied research.
Dr Judith Lacey is the Head of Supportive Care and Integrative Oncology at Chris O’Brien Lifehouse…
Dr Judith Lacey is the Head of Supportive Care and Integrative Oncology at Chris O’Brien Lifehouse. Her primary interest is in the development and integration of supportive care interventions to keep people living well with cancer independent of prognosis or stage of disease. Over the past 18 years she has worked extensively with cancer patients and people living with incurable illness. Her area of interest is in whole person care: integrating care for people and their families living with cancer or chronic illness that affects their physical and emotional well-‐being. She works with complementary and integrative medicine practitioners, psychologists, other medical specialists, nurses and allied health professionals to maximise patient wellbeing. As a Palliative and Supportive Care Specialist she has extensive experience in managing cancer pain syndromes, cancer related fatigue, gastrointestinal and nutritional effects of cancers and treatment related toxicities. Research interests and activities are in the field of Integrative oncology, Medicinal Cannabis, Supportive Care service developments .
Dr Judith Lacey is the Head of Supportive Care and Integrative Oncology at Chris O’Brien Lifehouse . Her primary interest is in the development and integration of supportive care interventions to keep people living well with cancer independent of prognosis or stage of disease. Over the past 18 years she has worked extensively with cancer patients and people living with incurable illness. Her area of interest is in whole person care: integrating care for people and their families living with cancer or chronic illness that affects their physical and emotional well-‐being. She works with complementary and integrative medicine practitioners, psychologists, other medical specialists, nurses and allied health professionals to maximise patient wellbeing. As a Palliative and Supportive Care Specialist she has extensive experience in managing cancer pain syndromes, cancer related fatigue, gastrointestinal and nutritional effects of cancers and treatment related toxicities. Research interests and activities are in the field of Integrative oncology, Medicinal Cannabis, Supportive Care service developments.
She is a member of the Multinational Association of Supportive Cancer Care, Society of Integrative Oncology, Sydney Catalyst Translational Cancer research centre, Australasian Lung Cancer Trials Group and Royal College of Physicians Medicinal Cannabis reference group . She has been involved in integration and policy development of palliative and supportive care services and more recently, integrative oncology in major health care systems in NSW. She has experience in both qualitative and quantitative research primarily in supportive cancer care. Her publications and research include: Integrative Oncology and Supportive Cancer Care, Coping with uncertainty and incurable cancer, symptom control and measuring QOL for the gynae-‐oncology patient, the role of the oncologist in care for the dying, palliative medicine as a public health issue, communication needs of cancer patients and couples and an associate investigator on a number of national studies evaluating medications and management of cancer related symptoms. She is a convenor and cofounder of the national whole person care program, workshops in Supportive Cancer Care and has held various expert advisory roles regarding palliative and supportive care service delivery and development for the cancer institute, cancer council and other bodies in Australia.
Dr Teresa Nicoletti leads Mills Oakley’s Intellectual Property, Health and Life Sciences team in Sydney…
Dr Teresa Nicoletti leads Mills Oakley’s Intellectual Property, Health and Life Sciences team in Sydney. She is both a lawyer and PhD-qualified scientist with 25 years’ experience in the health and life sciences sector, and has advised clients across the pharmaceutical, medical device, food and cosmetic industries in Australia and New Zealand. She is a recognised leader in her field and is particularly regarded as Australia’s leading expert in the regulation of therapeutic goods, cosmetics, medicinal cannabis and hemp.
In 2016, Teresa won the inaugural Lawyers Weekly Partner of the Year award for Health and took out the same award in 2017. She is also listed in Best Lawyers 2018 in the Life Sciences Category and obtained the highest possible Band 1 ranking in the Life Sciences Category in Chambers Asia Pacific 2018 and 2019.
Dr Scott Smid is a pharmacologist specialising in preclinical drug discovery and development research in both industry and academic settings…
Dr Scott Smid is a pharmacologist specialising in preclinical drug discovery and development research in both industry and academic settings. He maintains a strong research interest in experimental therapeutics applied towards novel treatments for gastrointestinal and neurodegenerative diseases. This includes investigating the biological actions of phytocannabinoids, synthetic cannabinoids and endocannabinoids in areas as diverse as gut function, inflammation and neurodegeneration. He has received US and Australian research funding to investigate the potential of cannabinoids as novel treatments for inflammation and dementia and has scientific advisory and education roles to government, industry and representative bodies for medical cannabis in Australia.
Dr Melissa Benson joined the Lambert Initiative in July 2018, where she continues to contribute to ongoing preclinical epilepsy research…
Dr Melissa Benson graduated with a Bachelor of Biotechnology (Honours in Drug, Design and Development) at the University of Queensland. Following this, she completed her PhD in Neuropharmacology also at the University of Queensland with a focus on the development of novel antiepileptic drug pathways and the role played by neuroinflammation in epilepsy disease development. She completed further postgraduate studies in Business related to drug development and intellectual property commercialisation.
Melissa then moved to NYC and undertook a postdoctoral fellowship at New York Medical College, focusing on disease mechanisms underlying West Syndrome, a catastrophic infantile epilepsy. Following her return to Australia, she worked in clinical trials management at a large private practice in eastern Sydney, focusing on day-to-day management and setup of clinical studies, primarily in the fields of HIV, hepatitis and cervical cancer.
Melissa joined the Lambert Initiative in July 2018, where she continues to contribute to ongoing preclinical epilepsy research. However, her key focus is project management of cannabinoid-based clinical trials and related projects being undertaken by the Lambert Initiative, in collaboration with specialist clinicians and researchers locally and abroad.
A senior executive with an extensive background in the not-for-profit human services sector spanning 35 years; holding chief executive and general management roles…
A senior executive with an extensive background in the not-for-profit human services sector spanning 35 years; holding chief executive and general management roles; responsibility for client services, revenue generation, branding, marketing, research and communications; significant merger and organisation re-design experience; providing strong leadership to high performing teams; demonstrated strong commitment to human rights; Fellow of the Australian Institute of Management.
Michael John (Mick) Palmer is a barrister and 33 year career police officer with extensive experience in police leadership and reform in community…
Michael John (Mick) Palmer is a barrister and 33 year career police officer with extensive experience in police leadership and reform in community, national and international policing.
Having progressed through the ranks of the Northern Territory Police Service, he was appointed Commissioner of the Northern Territory Police, Fire and Emergency Services agency in 1988 and served in that position until 1994 when he was appointed Commissioner of the Australian Federal Police (AFP). Mr Palmer held this position for 7 years until his retirement in March 2001.
In 1982 and 1983 Mr. Palmer practiced as a barrister at law in Queensland during a five year break in his police service.
Between 1997 and 2000 he was a member of the Executive Committee of Interpol having become the first Australian elected to the position. He was also the inaugural Deputy Chair of the National Council against Drugs (NCAD) a position he occupied until his retirement from policing in 2001.
Since retiring from policing in 2001 Mick has conducted a range of inquiries and reviews for the Australian Federal and State Governments, both within Australia and overseas.
In 2004/5 he conducted the Inquiry into the Circumstances of the Immigration Detention of Cornelia RAU and recently conducted an inquiry for the Tasmanian Government into conditions in the maximum security prison at Risdon in Hobart, Tasmania.
Between 2004 and 2012 he was the Federal Government’s Inspector of Transport Security, a position created after the 9/11 and Bali bombing terrorist incidents.
Mr Palmer is a recipient of the Australian Police Medal and in 1998 was admitted to the Order of Australia (AO) for his work in “advancing the professionalisation of policing through the introduction of far-reaching anti-corruption processes and management practice reform”.
In 1999 the Board of Governors of Charles Sturt University conferred the award of Doctor of Letters (honoris causa) for his contribution to advancing policing in Australia.
He is currently a member of the Board of Australia 21
Greg Barns is a barrister and writer. He is former National President of the Australian Lawyers Alliance and practices in the areas of criminal law, family law and administrative law…
Greg Barns is a barrister and writer. He is former National President of the Australian Lawyers Alliance and practices in the areas of criminal law, family law and administrative law. He is a former senior political adviser and the author of 3 books on Australian politics. He ran the 1999 Republic Referendum campaign and was National Chair of the Australian Republican Movement from 2000-02. Greg is a weekly columnist with the Hobart Mercury and writes regularly for other outlets. Greg is also an adviser to Wikileaks and Julian Assange. He is a Spokesperson for the Australian Lawyers Alliance.
While National President of the Lawyers Alliance he advocated legalization of drugs and has consistently called for drug policy based on evidence.
Jonathon Arnold is the Associate Director of Preclinical Research, and has a primary focus on strategic direction and execution of the Lambert Initiative’s preclinical research program…
Associate Director, Preclinical Research
Jonathon Arnold is the Associate Director of Preclinical Research, and has a primary focus on strategic direction and execution of the Lambert Initiative’s preclinical research program. He also works closely with the clinical research team to assist in the development and translation of research findings. Jonathon leads various Lambert Initiative projects which examine the efficacy of cannabinoids and full-spectrum cannabis extracts in preclinical models of disease including childhood epilepsy, cancer and Post-Traumatic Stress Disorder (PTSD). He is also exploring the role of the endogenous cannabinoid system in various diseases.
Jonathon brings considerable expertise in cannabis research and cannabinoid pharmacology to the academic leadership team. Jonathon has been Head of the Cannabinoid Research Group in the Sydney Medical School since 2002 and has published over 60 research papers that have received more than 2000 citations. His first major discovery was that plant cannabinoids reverse resistance to anticancer drugs. He has also isolated several genes that modulate the effects of cannabinoids on the brain and contributed to Australia’s first cannabis potency study, showing that Australian street cannabis is among the most potent in the world. More recently he has published research on interplay between CBD and THC which may contribute to ‘the entourage effect’.
In addition, Jonathon contributes to community outreach and education. He has incorporated cannabis research into the curriculum of Science and Medicine degrees at the University of Sydney. He has also supervised eight PhD students whose theses addressed cannabis research.
A former General Counsel with a decade of experience in commercial and intellectual property law, he founded the pro bono initiative that has since evolved into the Australian Medicinal Cannabis Legal Service (AMCLS)…
Mat is a former General Counsel with a decade of experience in commercial and intellectual property law.
In April 2018, he founded the pro bono initiative that has since evolved into the Australian Medicinal Cannabis Legal Service (AMCLS). He assists patients across Australia in a variety of civil and criminal matters and liaises with patient-advocates on various research initiatives.
His panel talk will look at recent developments in the law of Medical Necessity and explore the varying attitudes to medicinal cannabis in courts around the country and explain what this means for patients, industry and regulators. Mat is currently a Research Associate and Instructor at the Faculty of Law at La Trobe University.
Rita is a Registered Nurse whose nursing career spans work in many countries including UK, USA, France, Holland and Australia over 35 years…
Rita is a Registered Nurse whose nursing career spans work in many countries including UK, USA, France, Holland and Australia over 35 years. She has clinical backgrounds in ICU, palliative care, Aged Care, Emergency Department and Management.
She works as the Government and Community Relations organiser for the New South Wales Nurses and Midwives Association.
The New South Wales Nurses and Midwives’ Association (NSWNMA) is the registered union for all nurses and midwives in New South Wales. The membership of the NSWNMA comprises all those who perform nursing and midwifery work. This includes: registered nurses; enrolled nurses and midwives at all levels including management and education, and assistants in nursing/care workers (however titled, who are unregulated). The NSWNMA has approximately 64,500 members and is affiliated to Unions NSW and the Australian Council of Trade Unions (ACTU). Eligible members of the NSWNMA are also deemed to be members of the New South Wales Branch of the Australian Nursing and Midwifery Federation. Our role is to protect and advance the interests of nurses and midwives and the nursing and midwifery professions. We are also committed to improving standards of patient care and the quality of services in health and aged care services. The NSWNMA are proud to be associated and support the work of UIC.
The Australian Nursing and Midwifery Federation (ANMF) is Australia’s largest national union and professional nursing and midwifery organisation.
In collaboration with the ANMF’s eight state and territory branches, we represent the professional, industrial and political interests of more than 275,000 nurses, midwives and carers across the country.
Our members work in the public and private health, aged care and disability sectors across a wide variety of urban, rural and remote locations. We work with them to improve their ability to deliver safe and best practice care in each and every one of these settings, fulfil their professional goals and achieve a healthy work/life balance.
Our strong and growing membership and integrated role as both a trade union and professional organisation provide us with a complete understanding of all aspects of the nursing and midwifery professions and see us uniquely placed to defend and advance our professions.
Through our work with members we aim to strengthen the contribution of nursing and midwifery to improving Australia’s health and aged care systems, and the health of our national and global communities.
Friday 22nd Pass:
Saturday 23rd Pass
Sunday 24th Pass
3 Day Pass
Presented by Dr David Caldicott
The world premiere of ‘High as Mike’ – a documentary exploring the problems facing patient access to medicinal cannabis.
Screening included in 3 Day & Friday Symposium Entry
or purchase ticket separate
An exclusive pre-premiere drinks & canapes and a networking opportunity.
Mingle with Keynote speakers, special invited guests and the production team for ‘High as Mike’